|

SGLT2 inhibitor Clinical Trials

8 actively recruiting trials across 2 locations

Also known as: Canagliflozin, Invokana, canagliflozin, dapagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin +2 more

Pipeline

Phase 4: 3

Top Sponsors

University of Palermo1
University of Michigan1
Samsung Medical Center1
Kiyuk Chang1
Kafrelsheikh University1

Indications

Diabetes6
Heart Disease3
Diabetes Mellitus, Type 23
Heart Failure2
Chronic Kidney Disease Stage 21

Other6 trials

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients

Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes

Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention

Phase 4

SGLT-2 Inhibitors in the Treatment of Ascites

SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study

Baltimore, Maryland1 trial

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Johns Hopkins School of Medicine

Phase 4

Ann Arbor, Michigan1 trial

Mechanism of SGLT2 Inhibition in the Kidney

University of Michigan

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.